Clovis Oncology

Website:clovisoncology.com
Location:Boulder, CO United States
Revenue:$95.4M
Industry:Biotech
Founded:2009
Lead Investor(s):J. P. Morgan Securities LLC, BofA Merrill Lynch
Press

Current Growjo Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

We are a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, companion diagnostics intended to direct a compound in development to the population that is most likely to benefit from its use. Our first commercial product and lead product candidate, Rubraca® (rucaparib) tablets, is an oral, small molecule poly ADP-ribose polymerase, or PARP, inhibitor of PARP1, PARP2 and PARP3. Studies open for enrollment or under consideration include ovarian, prostate, breast, gastroesophageal, pancreatic, lung and bladder cancers. Clovis holds worldwide rights for Rubraca. In the United States, Rubraca is approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Rubraca is also approved in the United States for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic) associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Rubraca is an unlicensed medical product outside of the U.S. In addition, we have two other product candidates: lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3, and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor (?EGFR?). We maintain certain development and commercialization rights for lucitanib and global development and commercialization rights for rociletinib.

keywords:Biotechnology,Healthcare,Pharmaceuticals

451

Number of Employees

$95.4M

Revenue (est)

29

Current Jobs

22%

Employee Growth %

$763.3M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Clovis Oncology News

8-Mar-19 - Clovis Oncology holder Armistice trims stake to 3.8%

Clovis Oncology (NASDAQ:CLVS) shareholder Armistice Capital has filed an amended ownership statement saying it's holding a 3.8% stake in

27-Feb-19 - Here's Why Clovis Oncology Stock Jumped on Wednesday

Shares of Clovis Oncology (NASDAQ:CLVS), a biopharmaceutical company focused on oncology, notched some gains as investors digested

19-Feb-19 - Alkermes and Clovis Oncology Initiate Research Collaboration to

19, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that the companies have

Clovis Oncology Funding

DateAmountRoundLead InvestorsReference
2015-07-13$UndisclosedUndisclosedJ. P. Morgan Securities LLCArticle
2017-01-04$175.0MUndisclosedJ. P. Morgan Securities LLCArticle
2017-06-21$250.0MUndisclosedJ. P. Morgan Securities LLCArticle
2018-04-17$445.0MUndisclosedJ. P. Morgan Securities LLCArticle

Clovis Oncology Executive Hires

DateNameTitleReference
2016-01-26Dale HooksSVP/Chief Commercial OfficerArticle